Nasdaq btai.

View real-time BTAI stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... BioXcel Therapeutics, Inc. (NASDAQ:BTAI) dropped 21.2% to settle at $27.21 after Goldman Sachs downgraded the stock from Buy to Sell and lowered its price target from $55 to $24.Jun 29, 2023 · BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ... Discover historical prices for BTAI stock on Yahoo Finance. View daily, weekly or monthly format back to when BioXcel Therapeutics, Inc. stock was issued. ... Nasdaq Futures 15,961.50-47.25 (-0.30 ... BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) – Equities research analysts at HC Wainwright reduced their FY2023 EPS estimates for BioXcel Therapeutics in a research note issued to investors on Wednesday, November 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($6.63) per share for the year, down from […]

Nov 17, 2023 · On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days. NEW HAVEN, Conn., May 25, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...

BTAI U.S.: Nasdaq. BioXcel Therapeutics Inc. Watchlist. Alert. NEW. Set a price ... Real-time last sale data for U.S. stock quotes reflect trades reported through ...Shares of BioXcel Therapeutics ( BTAI 2.61%) had crashed 22.5% as of 11:56 a.m. EST on Monday. The steep decline came after Goldman Sachs ( GS 0.15%) analyst Corinne Jenkins downgraded BioXcel ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings results on Monday, August, 14th. The company reported ($1.83) earnings per share for the quarter, missing analysts' consensus estimates of ($1.72) by $0.11. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.42 million. 22 Aug 2023 ... (NASDAQ: BTAI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class ...NEW HAVEN, Conn., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Find the latest Earnings Report Date for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

586,279. 6.770742. Back to BTAI Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations ...

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...Headquartered in New Haven, Connecticut, Bioxcel Therapeutics (NASDAQ:BTAI) might not seem that impressive of an enterprise at first glance.Since the beginning of this year, BTAI slipped almost 1% ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary ...NEW HAVEN, Conn., Dec. 27, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for ...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. BioXcel Therapeutics, Inc. Common Stock (BTAI) Pre-Market Stock Quotes - Nasdaq ... BioXcel Therapeutics Inc (NASDAQ:BTAI) BioXcel Therapeutics Inc. 4.13. Delayed Data. As of Nov 17. -0.12 / -2.82%. Today’s Change. 2.23.

NEW HAVEN, Conn., Dec. 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...BTAI technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of BioXcel Therapeutics, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Learn more.BioXcel Therapeutics (NASDAQ:BTAI), a biopharma company based in Connecticut, leverages AI and machine learning to develop innovative treatments for central nervous system and immuno-oncology ...Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...NEW HAVEN, Conn., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing ...Jul 5, 2023 · Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioXcel Therapeutics Inc (Symbol: BTAI), where a total of 14,591 contracts have traded ...

Real time BioXcel Therapeutics (BTAI) stock price quote, stock graph, news & analysis. Over the past 3 months, 10 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Real time BioXcel Therapeutics (BTAI) stock price quote, stock graph, news & analysis.BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations ... Fintel reports that on July 3, 2023, HC Wainwright & Co. maintained coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation. Analyst Price Forecast Suggests 586.04% Upside. As of ...4 Jul 2023 ... Fintel reports that on July 3, 2023, HC Wainwright & Co. maintained coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy ...Nov 19, 2023 · BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) – Equities research analysts at HC Wainwright reduced their FY2023 EPS estimates for BioXcel Therapeutics in a research note issued to investors on Wednesday, November 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($6.63) per share for the year, down from […] Find the latest SEC Filings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ... Dec 19, 2022 · NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...

NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive ...

The big shareholder groups in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely ...

NEW HAVEN, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and ...BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...Following a 60% decline over last year, recent gains may please BioXcel Therapeutics, Inc. (NASDAQ:BTAI) institutional owners Read full article [email protected] (Simply Wall St)Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing.NEW HAVEN, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...markets.businessinsider.com - November 30 at 12:41 AM. BioXcel Therapeutics (BTAI) Price Target Increased by 5.88% to 14.28. msn.com - November 27 at 9:35 AM. BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $23.88 Average PT from Analysts. americanbankingnews.com - November 24 at 2:22 AM.BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 dated October 31, 2023.BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings results on Monday, August, 14th. The company reported ($1.83) earnings per share for the quarter, missing analysts' consensus estimates of ($1.72) by $0.11. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.42 million. Find the latest Insider Activity data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $11 price target. Why Beyond Air Shares Are Trading Lower ...

View Your Watchlist. Stock analysis for Bioxcel Therapeutics Inc (BTAI:NASDAQ CM) including stock price, stock chart, company news, key statistics, …NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...BTAI's recent financials show a net loss of $53.5MM for 2Q23, with a cash reserve expected to last until mid-2024. Strategic financing negotiations are underway. We maintain a hold rating on ...Marpai, Inc. Class A Common Stock (MRAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Instagram:https://instagram. nasdaq chdnwhat are the best ai stocks to buy nowhow to invest in startup companyaristocrat dividend NEW HAVEN, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) said the FDA has accepted for filing the new drug application for BXCL501, its investigational, orally dissolving thin film formulation of dexmedetomidine ... financial planner spokane wacox energy Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies Stocks fisher stock Nov 24, 2023 · BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ... BTAI: Get the latest BioXcel Therapeutics stock price and detailed information including BTAI news, historical charts and realtime prices. Indices Commodities Currencies Stocks